These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30120103)

  • 1. Baseline Cytokine Profiles of Tuberculin-Specific CD4
    Jallad S; Thomas P; Newport MJ; Kern F
    Cancer Immunol Res; 2018 Oct; 6(10):1212-1219. PubMed ID: 30120103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
    Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
    Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
    Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
    Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescence in situ hybridization as prognostic predictor of tumor recurrence during treatment with Bacillus Calmette-Guérin therapy for intermediate- and high-risk non-muscle-invasive bladder cancer.
    Liem EIML; Baard J; Cauberg ECC; Bus MTJ; de Bruin DM; Laguna Pes MP; de la Rosette JJMCH; de Reijke TM
    Med Oncol; 2017 Sep; 34(10):172. PubMed ID: 28866819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors.
    Sagnak L; Ersoy H; Ozok U; Senturk B; Ercil H; Bahar G; Ozturk E
    Clin Genitourin Cancer; 2009 Aug; 7(2):E16-23. PubMed ID: 19692317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic and immunologic determinants of intravesical BCG therapy in non-muscle-invasive urothelial bladder cancer].
    Krajewski W; Kołodziej A; Dembowski J; Zdrojowy R
    Postepy Hig Med Dosw (Online); 2014 Mar; 68():291-300. PubMed ID: 24662797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin.
    van der Meijden AP; Steerenberg PA; van Hoogstraaten IM; Kerckhaert JA; Schreinemachers LM; Harthoorn-Lasthuizen EJ; Hagenaars AM; de Jong WH; Debruijne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1989; 28(4):287-95. PubMed ID: 2784716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
    Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
    Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study.
    de Reijke TM; de Boer EC; Schamhart DH; Kurth KH
    Urol Res; 1997; 25(2):117-20. PubMed ID: 9144878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
    Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
    Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer.
    Zhong W; Wang B; Yu H; Lin J; Xia K; Hou W; Yang M; Chen J; Yang M; Wang X; Huang J; Lin T
    Oncoimmunology; 2020 Jun; 9(1):1776060. PubMed ID: 32923138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.